Keywords: Discrete choice experiment, hierarchical Bayesian model, benefit-risk
Assessment of benefit-risk should be a lifecycle process in drug development. Early input from stakeholders on tradeoffs between outcomes and/or utilities for different benefit and risk attributes can help to inform uncertainty in the development process. Ultimately, patients are an important voice in the benefit-risk balance that companies can consider. Discrete choice experiments offer a methodology that can have a relatively low cognitive burden, be used with patients or other stakeholders, and yield quantitative estimates of benefit-risk. A discrete choice experiment with hierarchical Bayesian modeling will be used to illustrate this approach.